There is information missing from the Competing interests statement. The Competing interests statement should read: Philip Bernard is an inventor of the PAM50 signature and a stakeholder in BioClassifier LLC, a company that licensed the PAM50 know-how to Nanostring Inc. for commercialization of Prosigna®. PB also has been a Medical Director at ARUP Laboratories Inc since 2003. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Reference
- 1.Bradford JR, Cox A, Bernard P, Camp NJ (2016) Consensus Analysis of Whole Transcriptome Profiles from Two Breast Cancer Patient Cohorts Reveals Long Non-Coding RNAs Associated with Intrinsic Subtype and the Tumour Microenvironment. PLoS ONE 11(9): e0163238 https://doi.org/10.1371/journal.pone.0163238 [DOI] [PMC free article] [PubMed] [Google Scholar]